A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
This study is investigating a new treatment approach for adults living with moderate to severe Crohn's Disease. Researchers want to find out if using two medicines together, vedolizumab and upadacitinib, is more effective at reducing inflammation and ulcers in the bowel than using vedolizumab by itself. They will also carefully monitor the safety of this combination treatment. For the first 12 weeks, all participants will receive vedolizumab along with either upadacitinib or an inactive dummy treatment (placebo). Those who respond well will then continue on vedolizumab alone for nearly a year. The study involves regular clinic visits and aims to advance our understanding of how to best treat Crohn's Disease.
En un coup d'œil
De quoi parle cette étude ?
This research study is for adults who have Crohn's Disease that is moderately to severely active. The main goal is to explore whether combining two medications, called vedolizumab and upadacitinib, works better than vedolizumab alone to help reduce inflammation and ulcers in the bowel. Researchers will also be carefully watching for any side effects and how safe the treatments are.
For the first 12 weeks, everyone in the study will receive vedolizumab. Half of the participants will also receive upadacitinib, and the other half will receive a placebo, which looks like upadacitinib but has no active medicine. This helps researchers compare the combination treatment with vedolizumab by itself. After these 12 weeks, if a participant's Crohn's disease shows a good response, they will then continue with vedolizumab alone for about 40 more weeks.
Understanding how different treatments work, alone or in combination, is crucial for improving care for people with Crohn's Disease. This study could help doctors make more informed decisions about the best ways to manage this condition in the future.
Points clés
- Tests vedolizumab with and without a second drug, upadacitinib.
- For adults with moderate to severe Crohn's Disease.
- Aims to reduce bowel inflammation and ulcers.
- Involves 15 clinic visits over about 70 weeks.
- Participants may receive a placebo in the initial phase.
- Careful monitoring of safety and effectiveness.
Qui peut être éligible ?
To join this study, you must be an adult between 18 and 65 years old with Crohn's Disease that has been diagnosed for at least three months. Your Crohn's disease must be considered moderately to severely active, and you should have signs of inflammation in your bowel, confirmed by special scans or tests.
It's important that previous treatments for your Crohn's disease, such as steroids, immune-suppressing drugs, or other biological medicines, haven't worked well enough for you, or you couldn't tolerate them.
There are also reasons why you might not be able to join. For example, if you have a different bowel condition like ulcerative colitis, or if you currently have a serious infection. Also, if you have certain complications from Crohn's Disease that might need surgery soon, such as blocked bowels or abscesses, or if you have severe kidney or liver problems, you wouldn't be able to take part.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous entre 18 et 65 ans ?
- Do you have a confirmed diagnosis of moderately to severely active Crohn's Disease?
- Have other Crohn's treatments not worked well for you or caused problems?
- Do you currently have a serious infection or severe kidney/liver problems?
- Do you have any severe complications from Crohn's that might need surgery soon?
En quoi consiste la participation ?
If you join this study, you'll be involved for about 70 weeks, which is roughly a year and four months. For the first 12 weeks, you'll receive a combination of medicines (vedolizumab plus either upadacitinib or a placebo). If your condition improves significantly, you'll then switch to receiving vedolizumab by itself for the next 40 weeks. After finishing the treatment, there will be a follow-up period of about 18 weeks to check on your health and safety. You will need to visit the study clinic about 15 times over the course of the study for check-ups and assessments.
Risques et avantages potentiels
Locations (138)
- UCSD Medical CenterCode postal vérifiéLa Jolla, United States· Pas encore en recrutement
- Keck Medicine Of USC - USC Healthcare Center 1Code postal vérifiéLos Angeles, États-Unis· Pas encore en recrutement
- Peak Gastroenterology AssociatesCode postal vérifiéColorado Springs, United States· Recrutement
- GI PROS, Inc.Code postal vérifiéNaples, États-Unis· Actif, mais pas en recrutement
- Orlando Health Ambulatory Care CenterCode postal vérifiéOrlando, United States· Actif, mais pas en recrutement
- USF Health Morsani Center for Advanced HealthcareCode postal vérifiéTampa, États-Unis· Actif, mais pas en recrutement
- Indiana University (IU) Health University HospitalCode postal vérifiéIndianapolis, États-Unis· Actif, mais pas en recrutement
- University of KentuckyCode postal vérifiéLexington, United States· Actif, mais pas en recrutement
- Mount Sinai Hospital - The Susan and Leonard Feinstein Inflammatory Bowel Disease (IBD) Clinical CenterCode postal vérifiéNew York, États-Unis· Actif, mais pas en recrutement
- Columbia University Medical Center, New York-Presbyterian HospitalCode postal vérifiéNew York, États-Unis· Pas encore en recrutement
- Lenox Hill Hospital Northwell HealthCode postal vérifiéNew York, États-Unis· Actif, mais pas en recrutement
- Gastroenterology AssociatesCode postal vérifiéGreenville, États-Unis· Actif, mais pas en recrutement
Questions fréquentes
What is Crohn's Disease?
Crohn's Disease is a long-term condition that causes inflammation in the digestive system, leading to symptoms like tummy pain, diarrhoea, and weight loss.
What are vedolizumab and upadacitinib?
These are medicines used to treat inflammatory conditions like Crohn's Disease by targeting specific parts of the immune system to reduce inflammation.
Que signifie 'placebo' ?
A placebo is an inactive substance or treatment that looks the same as the real medicine but contains no active drug. It helps researchers compare the effects of the active medicine.
Combien de temps durera l'étude ?
The entire study will last for approximately 70 weeks, which is about one year and four months.
Saurai-je quel traitement je reçois ?
During the first 12 weeks, you won't know if you're receiving upadacitinib or the placebo along with vedolizumab. This is standard in studies to ensure fair comparison of treatments.
Comment en savoir plus
Takeda Contact
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.